uniQure NV (uniQure NV) Total Inventories : $7.67 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Total Inventories?

uniQure NV's total inventories for the quarter that ended in Mar. 2024 was $7.67 Mil. uniQure NV's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $9.85 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. uniQure NV's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-1.15.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. uniQure NV's Days Inventory for the three months ended in Mar. 2024 was 97.40.

Inventory Turnover measures how fast the company turns over its inventory within a year. uniQure NV's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.94.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. uniQure NV's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.16.

uniQure NV Total Inventories Historical Data

The historical data trend for uniQure NV's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV Total Inventories Chart

uniQure NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

6.92

12.02

uniQure NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															7.48	10.21	15.65	12.02	7.67

uniQure NV Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

uniQure NV (NAS:QURE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

uniQure NV's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(555.683	+	0.75 * 10.717	+	0.5 * 7.672	-	623.296
-	0	-	0)	/	48.4924
=	-1.15

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

uniQure NV's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	9.848	/	9.226	*	365 / 4
	=	97.40

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

uniQure NV's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	9.226	/	9.848
	=	0.94

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

uniQure NV's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	9.848	/	8.485
	=	1.16

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

uniQure NV Total Inventories Related Terms

Thank you for viewing the detailed overview of uniQure NV's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

uniQure NV (uniQure NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

UQ1:Germany UQ1:Germany

Address

Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP

Website

https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Executives

Walid Abi-saab	officer: Chief Medical Officer	C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Ricardo Dolmetsch	officer: President, R&D	113 HARTWELL AVENUE, LEXINGTON MA 02421
Pierre Caloz	officer: Chief Operating Officer	UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Madhavan Balachandran	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Gut	director	C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post	director
Christian Klemt	officer: Chief Financial Officer	PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Jeremy P. Springhorn	director	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Matthew C Kapusta	director, officer: CEO, Managing Director	7358 MCVAY ROAD, GERMANTOWN TN 38138
Kuta Alexander Edward Iii	officer: Executive VP, Operations	239 WILLIS ROAD, SUDBURY MA 01776